At a glance
- Originator Forbes Medi-Tech
- Class Antihyperlipidaemics; Obesity therapies; Phytostanols
- Mechanism of Action Cholesterol absorption inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypercholesterolaemia; Obesity
Most Recent Events
- 27 May 2008 Discontinued - Phase-II for Hypercholesterolaemia in Netherlands (PO)
- 27 May 2008 Discontinued - Phase-II for Hypercholesterolaemia in USA (PO)
- 27 May 2008 Discontinued - Preclinical for Obesity in Canada (PO)